Articles tagged with Cancer Cells
Researchers discover a chromatin degrader that blocks cancer-causing genes, offering potential treatment for over 90% of prostate cancers. The study found that blocking the SWI/SNF complex slowed cancer cell growth and induced cell death, especially in tumors driven by FOXA1 or androgen receptor.
Scientists at La Jolla Institute for Immunology have discovered a link between TET enzyme deficiency and the formation of unusual DNA structures, such as G-quadruplexes and R-loops, which contribute to genomic instability. The study suggests that regulating these structures may be key to controlling cancer development.
A marine-dwelling creature, Trichoplax adhaerens, has been found to resist cancer and repair DNA after radiation damage. Researchers are exploring its unique properties to develop new therapies for cancer.
Researchers have identified NDUFS1 and ATP5O as novel markers of aggressive prostate cancer, associated with poorer survival rates. The study's findings provide new insights into the disease's molecular mechanisms and potential targets for therapy.
Researchers analyzed the largest cross-species database to assess species-specific cancer mortality rates and found conclusive proof that cancer risk is largely independent of body mass and life expectancy. The study highlights potent mechanisms of cancer resistance in larger species, contradicting intuitive expectations.
Researchers discover tBID can induce programmed cell death through mitochondrial damage, revealing a new function for a previously thought signal transducer protein. This finding has implications for treating malignant cells and combating infections like Shigella.
Scientists have developed a pioneering new technique to barcode individual cells more accurately and efficiently. The method combines artificial intelligence with microfluidics, allowing for real-time analysis of single cells and enabling the efficient sorting and counting of cells.
A recent study has identified a new mechanism by which oral cancer cells acquire radioresistance through the transfer of microRNA, specifically miR-503-3p. This discovery brings hope for the development of new treatments for radiation-resistant oral cancer.
Researchers have identified a novel immune-like mechanism by which healthy epithelial cells recognize and eliminate precancerous cells through a MHC class I-LILRB3 interaction. This process generates mechanical force to extrude the precancerous cells from the body, offering new hope for cancer prevention and treatment.
Researchers mapped how HTLV-1 transforms T-cells into cancerous cells, revealing the virus over-activates them and makes them more vulnerable to DNA damage. This study provides new directions for potential treatments to prevent cancer development.
Researchers identified specific metabolic vulnerabilities in leukemia cell lines, including sensitivity to PI3K and fatty acid synthase inhibitors. The study highlights the potential for targeted cancer therapy by exploiting these dependencies.
Researchers have discovered that NOR-1 protein can provide broad protection against heart damage following cancer treatment. Administering the protein directly may reduce heart risk, at least in laboratory tests.
Researchers analyzed 140 neuroblastoma samples to understand the genetic changes associated with the disease. They found that mutations can disappear and reappear, occurring in distinct sections or individual cells, making targeted therapy less effective.
Researchers identified three prototypical RNA-expression states in pancreatic cancer cells and found that altering the tumor microenvironment can drive tumor cells to become more susceptible to certain drugs. This discovery opens up new possibilities for personalized medicine and targeting specific drug responses.
Researchers have developed a CRISPR/Cas9 gene editing system to enhance the effectiveness of sonodynamic therapy, allowing tumors to be effectively shrunk in a mouse model of liver cancer. The technology reduces antioxidant defense systems, increasing cancer cell death from the treatment.
A recent study by NTU Singapore and Singapore General Hospital found that mutations in the DDX3X gene are responsible for chemotherapy resistance in some blood cancer patients. The study also discovered that STAT inhibitors can effectively kill lymphoma cells with DDX3X mutations, providing hope for new treatment options.
Researchers discovered a newly defined domain in a protein that regulates gene expression under high-energy conditions. Cells adapt to changing nutrient environments by switching between specialized gene expression programs, which are triggered by different molecular tags on histones.
Researchers identified a mechanism for how genetically defective cells mutate to survive stressful situations, such as drug treatment. Understanding this resistance mechanism could lead to the development of new strategies to delay or prevent cancer drug resistance.
Researchers at Tel-Aviv University have shed light on the Sigma-1 receptor's topology and function in neurodegenerative diseases. The study reveals that the receptor is retained in the endoplasmic reticulum and its amino end faces the cytoplasm, providing a crucial mechanism for therapeutic approaches to alleviate suffering from ALS.
A research team developed an AI framework that analyzes protein interactions to predict effective and low-toxicity cancer drug combinations. The framework, GraphSynergy, outperforms conventional models in identifying synergistic combinations.
The FDA has approved Cytalux, which enables surgeons to identify and remove cancerous lesions with greater precision. In a Phase 3 study, nearly 27% of women with confirmed ovarian cancer found at least one undetected lesion during surgery.
The study uses a new barcode system to track complex signaling activities in cancer cells and identify key protein interactions. The technique enables real-time analysis and synchronization of protein activity over time.
Researchers at Saarland University have discovered that the lipid and cholesterol metabolism of immune cells collaborating with tumour cells is severely compromised compared to tumour tissue. This finding suggests a possible explanation for why cholesterol-lowering drugs are ineffective against non-small-cell lung carcinoma.
A recent review article describes a class of viruses known as oncolytic viruses, which have the remarkable ability to target and destroy cancer cells. Researchers are exploring these viruses for cancer therapy, with some showing promising results in stimulating an immune response against cancer.
A study found that the MYCN protein creates conflicts between DNA replication and transcription in cancer cells, leading to increased division rates and potential damage. The researchers hope to develop therapies by disrupting the cooperation between MYCN and a molecule called BRCA1.
Researchers discovered that under stress conditions, proteasome molecules assemble into structures that induce cell death, a process linked to apoptosis and potentially preventing cancer. The study highlights the importance of understanding the normal functioning of cells and their connections to cancer development.
A systematic review of bitter taste receptors in cancer found that overexpression of these receptors stimulates anti-cancer mechanisms, reducing cell division and migration while increasing programmed cell death. Conversely, downregulation of bitter taste receptor genes is common in cancer cells.
Researchers from the University of Copenhagen have discovered a natural substance, a flavonoid, that can inhibit cancer cells' ability to defend themselves against chemotherapy by targeting efflux pumps. This could lead to more effective treatment and potentially even combat antibiotic resistance.
Cryo-EM study reveals details of DNA repair mechanism translesion synthesis (TLS), allowing cells to survive with mutations. Key protein complex Pol K - PCNA interaction modulated by ubiquitination facilitates recruitment of TLS polymerase to damage sites.
Researchers at Karolinska Institutet found that CRISPR gene-editing causes DNA damage, activating the p53 protein, which can lead to an accumulation of mutated cancer cells. The study identified a network of linked genes with similar mutations and suggests transient inhibition of p53 as a potential strategy to prevent their enrichment.
A functional precision medicine study demonstrates that treatment selection based on results from drug sensitivity testing can be clinically useful in patients with aggressive hematological cancer. The approach combines deep molecular profiling with comprehensive drug sensitivity testing to advance the therapy decision-making system.
Researchers have developed fish-shaped microrobots that can guide themselves to cancer cells using magnets, where a pH change opens their mouths to release chemotherapy. The microrobots demonstrate promising capabilities for targeted cancer treatment, but need further improvements in size and tracking methods.
Researchers have developed a new approach to studying prostate cancer, allowing them to track the behavior of individual cancer cells from birth to organ spread. The technique uses whole-organ imaging and artificial intelligence to create a 3D reconstruction of the organ at single-cell resolution.
A researcher at MUSC's Hollings Cancer Center is developing 'living drugs' by precision-engineering CAR Tregs to treat autoimmune diseases. The CAR Tregs can delay or reduce damaging inflammation, offering a potential solution for conditions like Type 1 diabetes.
A recent study by Sanford Burnham Prebys and the National Cancer Institute has shown that CRISPR-Cas9 gene editing can favor cells with mutated forms of genes linked to cancer. This highlights the importance of monitoring patients undergoing CRISPR-based gene therapy for cancer-related mutations.
Researchers at University of Göttingen investigate tight junctions' importance in cell movement and their consequences when missing. The findings suggest a 'tug of war' scenario between cells with unequal contraction and stretching, affecting tissue mobility and biological functions.
Researchers developed a blood test that can detect prostate cancer patients who are resistant to chemotherapy drug docetaxel, enabling early detection and personalized treatment. The test analyzes circulating tumor cells in the bloodstream, revealing patterns that predict disease progression and survival.
A research team at the University of Montreal Hospital Research Centre has found that cellular aging is caused by irreversible damage to the genome, not just telomere erosion. This discovery challenges the long-held scientific model and opens up new research opportunities for preventing cellular aging and genomic instability.
Researchers at Johns Hopkins Kimmel Cancer Center found a new treatment option for inoperable pleural mesothelioma using immunotherapy agent durvalumab combined with platinum-based chemotherapy. Patients with epithelioid tumors experienced higher survival rates, including some who remained tumor-free after completing the trial.
Researchers discovered a new biomarker, inactive AMPK (lo-P-AMPK), that may predict immune evasion in lung cancer. The finding could enable better personalized care for lung cancer patients by identifying those most likely to benefit from immunotherapies.
A new machine learning model developed by Timothy Chan accurately predicts whether immune checkpoint blockade will be effective in patients with various cancers. The tool assesses multiple patient-specific factors, including tumor mutational burden and chemotherapy history, to predict response and survival outcomes.
Researchers at Children's Hospital of Philadelphia have developed a novel therapy that targets proteins essential for tumor growth and survival. Using a multi-omics approach, they identified peptides unique to neuroblastoma tumors, which are then targeted by peptide-centric chimeric antigen receptors (PC-CARs).
Researchers are developing a transformative technology called Multiscale Intelligent Convergence (MusIC) to map the complexity of T cells and identify attributes essential for patient benefit. The goal is to create more reliable biomanufacturing of T cell infusion products and engineering potent immune cells.
Researchers discovered that pancreatic injury leads to the formation of new cell types that can give rise to cancerous mutations. The study provides a valuable resource for understanding the processes behind pancreatic cancer and potential therapeutic targets.
Researchers found that certain T cells stop working before entering the tumor due to changes in gene expression, making ICB therapies less effective. Combining ICB with other forms of immunotherapy targeting different aspects of T cell function may improve response rates for non-small cell lung cancer patients.
Researchers developed a new NMR spectroscopic method to map IDP function more easily, fast, and accurately. The method sheds light on mechanisms of diseases like Parkinson's, Alzheimer's, and type 2 diabetes.
Researchers describe how cancer cells exploit genetic and cellular processes to promote tumor survival and growth. The study found that aneuploidy, a condition of abnormal chromosome number, intersects with the stress response mechanism in cancer cells, leading to immune cell dysregulation.
A new study identifies three functional subtypes of cancer-associated fibroblasts (CAF) in lung cancer, which correspond to patients' treatment responses. These subtypes have distinct biological functions and therapeutic implications, suggesting that CAFs could serve as a key to enhancing personalized treatment for lung cancer patients.
Researchers discovered cells can regulate neighboring cell stiffness to facilitate movement, a finding that could aid in understanding developmental disorders and cancer metastasis. This novel mechanism may provide a strategy for slowing or preventing cancer spread by altering tissue stiffness.
Researchers have developed nanoparticles that can communicate with and slow the development of cancer cells. The nanoparticles aggregate in cancer cells, reducing metabolic activity and growth, and are activated by MMP-9 enzyme secreted by cancer cells.
Researchers create maps of senescence in heart and lung cells, comparing different types of senescent cells across the lifespan. The goal is to understand how senescent cells contribute to age-related diseases and develop therapies called senolytics.
Researchers at Yale Cancer Center are launching a new tissue mapping center to study the role of senescent immune cells in development, aging, and disease. The goal is to develop strategies to target senescent cells to battle aging and cancer.
Researchers discovered that leukemia cells immediately unresponsive to treatment have high levels of SAMHD1, while those with acquired resistance use the enzyme DCK to activate nucleoside analogues. This finding may lead to better cancer therapies.
Scientists at the University of Cambridge have found that T cell mitochondria regulate the refuelling of toxic weapons, enabling killer T cells to stay healthy and keep killing. This discovery sheds light on how these immune system assassins are able to sustain their deadly missions.
A team of scientists from the University of Pittsburgh and National Cancer Institute discovered why HIV is rarely the direct cause of cancer. The research found that it requires a specific series of events involving changes in HIV and additional mutations in human genes, resulting in T cell lymphomas. However, the occurrence is rare, a...
Researchers used CRISPR/dCas9 technology to target DNA methylation and study its effects on cancer cell behavior. The study found that the same epigenetic modification can lead to opposing expression profiles of a target gene in different cancer cell models.
Researchers have discovered a way to bring cancer-killing T cells to bear against a specific type of colorectal cancer, showing promising results. The findings may represent a therapeutic strategy to target other types of cancers, and the next step is to further explore how T cells become activated in the tumor environment.
Researchers have discovered a new drug target for myelodysplastic syndrome (MDS) and other hematologic malignancies, which are sensitive to MEK inhibitors. The study found that mutations affecting RNA splicing alter cells to develop MDS and solid tumors, providing a potential new approach to treating this rare blood cancer.
MUSC researcher Haizhen Wang receives R37 grant to investigate CDK6's role in T-cell acute lymphoblastic leukemia, a aggressive cancer. The research aims to understand how the immune system can be used to reduce leukemia progression.
A clinical trial found that obese prostate cancer patients who underwent regular exercise training for 12 weeks had increased levels of anti-cancer myokines, which suppressed tumour growth and helped fight cancerous cells. The study suggests exercise may be a key weapon in cancer patients' battle against the disease.